Moreover, multiple studies involving NSCLC patients treated with various aPD-1/aPD-L1-based therapies also observed a negative correlation between post-treatment CEA and cytokeratin 19 fragment antigen21-1(CYFRA21-1) levels and PFS or OS [23–25]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.